2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease

Autoria(s): Besse, B.; Adjei, A.; Baas, P.; Meldgaard, P.; Nicolson, M.; Paz-Ares, L.; Reck, M.; Smit, E.F.; Syrigos, K.; Stahel, R.; Felip, E.; Peters, S.; Stahel, R.; Felip, E.; Peters, S.; Kerr, K.; Besse, B.; Vansteenkiste, J.; Eberhardt, W.; Edelman, M.; Mok, T.; O'Byrne, K.; Novello, S.; Bubendorf, L.; Marchetti, A.; Baas, P.; Reck, M.; Syrigos, K.; Paz-Ares, L.; Smit, F.E.; Meldgaard, P.; Adjei, A.; Nicolson, M.; Crinò, L.; Van Schil, P.; Senan, S.; Faivre-Finn, C.; Rocco, G.; Veronesi, G.; Douillard, J.Y.; Lim, E.; Dooms, C.; Weder, W.; De Ruysscher, D.; Le Pechoux, C.; De Leyn, P.; Westeel, V.
Data(s)

01/08/2014
Resumo

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Identificador

http://eprints.qut.edu.au/78356/
Publicador

Oxford University Press
Relação

DOI:10.1093/annonc/mdu123

Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E.F., Syrigos, K., Stahel, R., Felip, E., Peters, S., Stahel, R., Felip, E., Peters, S., Kerr, K., Besse, B., Vansteenkiste, J., Eberhardt, W., Edelman, M., Mok, T., O'Byrne, K., Novello, S., Bubendorf, L., Marchetti, A., Baas, P., Reck, M., Syrigos, K., Paz-Ares, L., Smit, F.E., Meldgaard, P., Adjei, A., Nicolson, M., Crinò, L., Van Schil, P., Senan, S., Faivre-Finn, C., Rocco, G., Veronesi, G., Douillard, J.Y., Lim, E., Dooms, C., Weder, W., De Ruysscher, D., Le Pechoux, C., De Leyn, P., & Westeel, V. (2014) 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease. Annals of Oncology, 25(8), pp. 1475-1484.
Direitos

Copyright 2014 Oxford University Press
Fonte

School of Biomedical Sciences; Faculty of Health; Institute of Health and Biomedical Innovation
Palavras-Chave #111200 ONCOLOGY AND CARCINOGENESIS #Consensus #Esmo #Further lines #Non-small-cell lung cancer #afatinib #bevacizumab #carboplatin #cisplatin #cisplatin derivative #crizotinib #dabrafenib #denosumab #docetaxel #epidermal growth factor receptor #erlotinib #gefitinib #gemcitabine #mitomycin #navelbine #paclitaxel #pemetrexed #placebo #sorafenib #taxane derivative #trastuzumab #vandetanib #vinblastine #zoledronic acid #adenocarcinoma #advanced cancer #article #blood toxicity #bone metastasis #brain metastasis #cancer chemotherapy #cancer growth #cancer incidence #cancer staging #cancer survival #consensus development #drug efficacy #drug rechallenge #drug substitution #drug tolerability #drug withdrawal #febrile neutropenia #gain of function mutation #gene mutation #gene rearrangement #human #lung non small cell cancer #maintenance therapy #meta analysis (topic) #monotherapy #multiple cycle treatment #mutation #neutropenia #phase 3 clinical trial (topic) #primary medical care #priority journal #progression free survival #quality of life #randomized controlled trial (topic) #secondary health care #treatment response #unspecified side effect
Tipo

Journal Article
Acesso ao item digital